fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Updated results from pivotal HER2CLIMB trial evaluating Tukysa in patients with HER2-positive breast cancer – Seagen Inc

Written by | 6 Feb 2022

Seagen Inc. announced the presentation of new data from exploratory analyses from the pivotal HER2CLIMB trial showing that improvement in overall survival (OS) was maintained after an additional… read more.

Enhertu reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer – AstraZeneca + Daiichi Sankyo

Written by | 28 Sep 2021

Ground-breaking Phase III head-to-head DESTINY-Breast03 results featured at ESMO Presidential Symposium support Enhertu as the potential new standard of care in previously treated patients. DESTINY-Breast01 Phase II trial… read more.

SOPHIA Phase III study of Margenza announces final OS data in HER2-positive breast cancer patients – MacroGenics

Written by | 15 Sep 2021

MacroGenics announced the final overall survival (OS) results of the SOPHIA Phase III study of Margenza (margetuximab-cmkb) in adult patients with metastatic HER2-positive breast cancer. The final OS… read more.

Seagen announces long-term results from Tukysa pivotal trial for HER2-positive breast cancer during the 2021 ASCO Annual Meeting

Written by | 11 Jun 2021

Seagen Inc. announced that improvements in overall survival (OS) and progression-free survival (PFS) were maintained with long-term follow up from the pivotal HER2CLIMB trial evaluating the addition of… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.